Literature DB >> 10025799

HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy.

D B Clifford1, C Yiannoutsos, M Glicksman, D M Simpson, E J Singer, P J Piliero, C M Marra, G S Francis, J C McArthur, K L Tyler, A C Tselis, N E Hyslop.   

Abstract

Introduction of highly active antiretroviral therapy (HAART) has been associated with many changes in the complications of human immunodeficiency virus (HIV) infection. A cohort of 25 HIV patients with progressive multifocal leukoencephalopathy (PML) treated with HAART experienced a median survival of >46 weeks. This is an improvement in prognosis compared with recent historic experience and correlated with HIV RNA viral load reductions. We conclude that current HIV therapy is important in improving the outlook of PML in the setting of HIV.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10025799     DOI： 10.1212/wnl.52.3.623

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  72 in total

1.  Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART).

Authors:  M Maschke; O Kastrup; S Esser; B Ross; U Hengge; A Hufnagel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

2.  The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy.

Authors:  P Cinque; C Pierotti; M G Viganò; A Bestetti; C Fausti; D Bertelli; A Lazzarin
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

Review 3.  Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy.

Authors:  C T Yiannoutsos; A De Luca
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

4.  The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS.

Authors:  M D Geschwind; R I Skolasky; W S Royal; J C McArthur
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

Review 5.  Challenges for clinical trials on progressive multifocal leukoencephalopathy.

Authors:  D B Clifford
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

6.  Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?

Authors:  Renaud A Du Pasquier; Igor J Koralnik
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

Review 7.  Challenges for clinical trials to treat progressive multifocal leukoencephalopathy.

Authors:  David B Clifford
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

8.  A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy.

Authors:  Nobuo Sanjo; Yurie Nose; Yukiko Shishido-Hara; Saneyuki Mizutani; Yoshiki Sekijima; Hitoshi Aizawa; Toru Tanizawa; Takanori Yokota
Journal:  J Neurol       Date:  2018-12-03       Impact factor: 4.849

9.  Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.

Authors:  J Kuhle; R Gosert; R Bühler; T Derfuss; R Sutter; O Yaldizli; E-W Radue; C Ryschkewitsch; E O Major; L Kappos; S Frank; H H Hirsch
Journal:  Neurology       Date:  2011-11-09       Impact factor: 9.910

10.  Use of diffusion-weighted imaging to evaluate the initial response of progressive multifocal leukoencephalopathy to highly active antiretroviral therapy: early experience.

Authors:  C Buckle; M Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-01       Impact factor: 3.825
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.